Building a true strategy about your pharmaceutical drugability 
Years of experience
Clients
Studied molecules
Clarified strategies in terms of scope and prioritisation between studies
Shortened timelines for selecting higher value drug candidates
Lower risk in early development programs and optimisation of R&D costs
Higher project team autonomy in regulatory preclinical and clinical development
Enhanced chances for a much higher project valorisation
Latest news
AFSSI Connections 2021
J-10 avant les 8èmes AFSSI connections, qui se tiendront cette année à nouveau en distanciel ! L’occasion d’échanger avec les membres de l’AFSSI, partenaires de la R&D en santé lors de 2...
more news>